Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

Inclusion Criteria: * Histologically confirmed squamous cell lung cancer * Newly diagnosed untreated Stage IV and/or recurrent after adjuvant therapy with metastatic disease * Patients previously treated with immune checkpoint inhibitor therapy are eligible * Measurable disease as per RECIST 1.1 * Greater than 6 months since receiving neo-adjuvant or adjuvant chemotherapy. * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Women of childbearing potential and sexually active men enrolled in the study must agree to practice effective contraception method during treatment and for three months after completing treatment * Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential * \< Grade 2 pre-existing peripheral neuropathy (per CTCAE) * Marrow and organ function as follows: * ANC ≥ 1500 cells/mm3 * Platelets \> 100,000 cells/mm3 * Hemoglobin\>9g/dL * Creatinine clearance ≥ 40mL/min * Bilirubin ≤ 1.5 mg/dL * AST/ALT≤2.5 x upper limit of normal range (ULN), * alkaline phosphatase ≤ 2.5 X upper limit of normal, unless bone metastasis in present in the absence of liver metastasis Exclusion Criteria: * Prior treatment with albumin-bound paclitaxel or gemcitabine * Prior systemic anticancer therapy for advanced squamous cell lung cancer * Untreated brain metastasis. Patients with treated brain metastases who are off steroids are eligible * Peripheral neuropathy greater than grade 1 * Malignancies within the past 5 years other than non-melanoma skin cancer or insitu cervical cancer status post treatment * Patients with other serious medical illnesses including, ongoing or active infection, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements * Class III or IV congestive heart failure by New York Heart Association